WC
ITCI icon

Wexford Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Wexford Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-37,994
Closed -$1.48M – 188
2016
Q2 		$1.48M Hold
37,994
– – 0.26% 64
2016
Q1 		$1.06M Buy
+37,994
New +$1.27M 0.21% 73

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Hillhouse Investment Management
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Wexford Capital's ITCI Position: Q3 2016 in Review

Wexford Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2016, closing a stake of 37,994 shares — an estimated $1.48M sold.

Wexford Capital first reported a position in ITCI in Q1 2016 and held it in 2 quarters. The position peaked at $1.48M in Q2 2016. 132 funds tracked by Wall St. Rank hold ITCI as of Q3 2016.

  • Wexford Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2016 after selling out during the quarter.
  • Wexford Capital sold 37,994 Intra-Cellular Therapies Inc. shares in Q3 2016, an estimated $1.48M.
  • Wexford Capital first reported a position in Intra-Cellular Therapies Inc. in Q1 2016 and held it in 2 quarters.
  • Wexford Capital's Intra-Cellular Therapies Inc. position peaked at $1.48M in Q2 2016.
  • 132 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2016.

Based on Wexford Capital's 13F filing for Q3 2016, filed 14 Nov 2016.